NeuroMab™ Anti-EPHA2 BBB Shuttle Antibody(NRZP-1022-ZP3866)

Figure 1 shows the presence or absence of ADCC activity of anti-EPHA2 antibodies against various cell lines.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing ADCC activity against MDA-MB-231 cells.

Figure 2 shows the CDC activity of anti-EPHA2 antibodies against various cells.

Figure 3 is a graph showing the antitumor activity of SH348-1 in mice transplanted with MDA-MB-231 cells.

Figure 4 is a diagram showing the binding activity of SH348-1 and EPHA2 extracellular domain polypeptide.

Figure 5 is a graph showing the ligand-binding inhibitory activity of SH348-1, SH357-1, and Ab96-1.

Figure 6 is a graph showing that SH348-1 and SH357-1 have ephrin-A1-dependent phosphorylation activity to inhibit EPHA2 tyrosine residues.

Figure 7 is a graph showing the reactivity of SH357-1 to EPHA2 deletion mutants.

Figure 8 is a graph showing the binding activity between hSH357-1-T1 and EPHA2 extracellular domain polypeptide.

Figure 9 is a graph showing the competitive inhibitory activity of hSH357-1-T1 and hSH357-1-T3 on SH357-1 antigen binding.

Figure 10 is a graph showing the activity of hSH357-1-T1 or hSH357-1-T3 to inhibit ephrin-A1-dependent phosphorylation of EPHA2 tyrosine residues.